AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy
Pays $200m Upfront
The UK major has been building its cell therapy portfolio for about three years internally, oncology R&D chief Susan Galbraith tells Scrip, and the purchase of Neogene and its TCR-Ts targeting neoantigens in solid cancers is a logical step.
You may also be interested in...
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
GSK is abandoning one of its new drug prospects after it failed in hard-to-treat rheumatoid arthritis patients at Phase III, raising the stakes for more key readouts due shortly.
The revenue boost Evusheld has given AstraZeneca over the past year will grind to a halt now that the FDA, as expected, has pulled approval for the antibody combo on the grounds it is ineffective against most SARS-CoV-2 variants circulating in the US.